Unveiling the role of ZIKV NS4A mutants F4L and E8D through molecular docking and dynamics simulation: implications

Afshan Salam1, Usama Ilahi1, Mian Hazrat Yousuf2

  • 1Center for Biotechnology and Microbiology, University of Swat, Swat, Pakistan.

In Silico Pharmacology
|January 12, 2026
PubMed

Insights

Zika virus (ZIKV) mutations F4L and E8D in the NS4A protein were found to enhance viral immune evasion. These mutations stabilize interactions with MAVS, potentially disrupting interferon induction and aiding ZIKV pathogenesis.

Area of Science:

  • Virology and Molecular Biology
  • Immunology
  • Computational Biology

Background:

  • Zika virus (ZIKV) poses a global health threat, linked to microcephaly and neurological issues.
  • The ZIKV non-structural protein NS4A is crucial for viral replication and immune evasion by inhibiting MAVS.
  • Understanding NS4A-MAVS interactions is key to ZIKV pathogenesis and therapeutic strategies.

Purpose of the Study:

  • To investigate the impact of specific NS4A mutations (F4L, E8D) on ZIKV's interaction with MAVS.
  • To assess how these mutations affect viral immune evasion mechanisms.
  • To provide a computational basis for targeting ZIKV NS4A.

Main Methods:

  • Molecular docking and 300 ns molecular dynamics simulations were employed.
  • Binding free energy calculations (MM/PBSA) were used to quantify interaction strengths.
  • Analysis of structural dynamics (RMSD, RMSF, Rg) and hydrogen bonding patterns was performed.

Main Results:

  • F4L and E8D mutations altered the conformational dynamics of NS4A-MAVS complexes.
  • Both mutants exhibited enhanced interaction networks with MAVS compared to the wild type.
  • F4L and E8D showed reduced binding affinities, with E8D demonstrating significant electrostatic contributions potentially disrupting interferon induction.

Conclusions:

  • The F4L and E8D mutations in ZIKV NS4A enhance immune evasion by stabilizing NS4A-MAVS interactions.
  • The E8D mutation, in particular, shows potential for disrupting MAVS-mediated interferon signaling.
  • These findings offer insights into ZIKV pathogenesis and suggest NS4A as a therapeutic target.